-
x
x
bid
ask
02:08 PM
Bearish
41
Bullish
159
sentiment
day range
52 week range
Prev Close
Open
Low
High
Volume0.00
Avg. Volume0.00
Market Cap0.00
Inst. Own
Beta
Short Ratio
Div & Yield /
EPS
P/E
1yr Target
50day MA
200day MA
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2532.75
05:59 AM
-
46.85
1.82%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
163.45
05:59 AM
+
6.50
4.14%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript) | seekingalpha.com • |
Biocept to Hold Business Update Conference Call on August 30, 2023 | businesswire.com • |
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole | investorplace.com • |
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference | proactiveinvestors.com • |
Biocept appoints Antonino Morales as president and chief executive officer | proactiveinvestors.com • |
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023 | businesswire.com • |
Profile
...
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-11-20 | 2023-09 | 0 | N/A | N/A | N/A |
2023-05-10 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-17 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-21 | 2022-09 | -4.8 | N/A | N/A | N/A |
2022-11-10 | 2022-06 | 0 | N/A | N/A | N/A |
2022-05-23 | 2022-03 | -7.21 | N/A | N/A | N/A |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-12-08 | HALE DAVID F | Director | 0.00 | Sale |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Anson Funds Management LP | 44.86K | 54.28K | 1.71% |
2023-06-29 | Boothbay Fund Management, LLC | 23.53K | 28.47K | 0.90% |
2023-06-29 | Tower Research Capital LLC (TRC) | 5.39K | 6.52K | 0.21% |
2023-06-29 | Blackrock Inc. | 5.26K | 6.37K | 0.20% |
2023-06-29 | Acadian Asset Management. LLC | 247.00 | 298.00 | 0.01% |
2023-06-29 | Group One Trading, L.P. | 270.00 | 326.00 | 0.01% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 4.43K | 5.37K | 0.17% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.95K | 6.38K | 0.11% |
2023-05-30 | Fidelity Series Total Market Index Fund | 644.00 | 1.39K | 0.02% |
2023-05-30 | Fidelity Total Market Index Fund | 488.00 | 1.05K | 0.02% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 189.00 | 408.00 | 0.01% |
Split
...
Split | Date |
---|---|
1 : 30 | 2023-05-17 |
1 : 10 | 2020-09-08 |
1 : 30 | 2018-07-10 |
1 : 3 | 2016-09-29 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Suck my balls BIOC
-
Move it!
-
Where’s everyone from Friday?
-
Wow. I’m not selling til 1.50. And you guys are selling for a penny
-
What just happened
-
That time it was this low it jumped 100%
-
Go up! stop fading
-
Let’s go!
-
Would love to wake up and this be up 200%
-
Adding here
-
Something needs to be fixed here
-
Can this just be bought out at 2.50 price
-
What happened
-
Still here holding long waiting for $2
-
You can’t sell here. That’s just dumb. Buying more now
-
Good job guys for fucking all the longs
-
How the fuck are you selling
-
They gonna buy now so this we’ll go back up
-
Y’all so negative
-
Oh fuck me
-
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
seekingalpha.com • -
Biocept to Hold Business Update Conference Call on August 30, 2023
businesswire.com • -
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
investorplace.com • -
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
proactiveinvestors.com • -
Biocept appoints Antonino Morales as president and chief executive officer
proactiveinvestors.com • -
Why Is Biocept (BIOC) Stock Down 42% Today?
investorplace.com • -
Biocept shares to commence trading on split-adjusted basis
proactiveinvestors.com • -
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Biocept reports 176% year-over-year jump in orders for CNSide assay
proactiveinvestors.com • -
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
proactiveinvestors.com • -
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
proactiveinvestors.com • -
Biocept to Hold Business Strategy Conference Call Today
businesswire.com • -
Biocept sees 1Q net revenue rise 12% driven by its coronavirus testing services
proactiveinvestors.com • -
Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
proactiveinvestors.com • -
Biocept reports unaudited net revenue of $61.2 million for 2021
proactiveinvestors.com • -
Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO
proactiveinvestors.com • -
Biocept appoints Darrell Taylor as its new chief compliance officer
proactiveinvestors.com • -
Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
proactiveinvestors.com • -
Biocept launches single test for COVID-19 and Influenza as cases rise during flu season
proactiveinvestors.com • -
Biocept sees profitability in third quarter thanks to increased RT-PCR COVID-19 testing
proactiveinvestors.com • -
7 of the Best Penny Stocks to Buy Coming Into Year-End
investorplace.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept reports profitability for the first half on back of increased COVID-19 testing
proactiveinvestors.com • -
Biocept appoints David Karlander as senior vice president of Commercial Operations
proactiveinvestors.com • -
Biocept bolsters board of directors and names Samuel D Riccitelli as new chairman
proactiveinvestors.com • -
Biocept joins the Russell Microcap Index
proactiveinvestors.com • -
Biocept Joins the Russell Microcap® Index
businesswire.com • -
Wall Street takes a turn for the worse as investors eye Fed
proactiveinvestors.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept makes coronavirus testing available for California's 116 community colleges
proactiveinvestors.com • -
Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer
proactiveinvestors.com • -
Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing
proactiveinvestors.com • -
Biocept: Record Revenues And Profits Support Speculative Buy
seekingalpha.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept: Q4 Earnings Insights
benzinga.com • -
Biocept to Participate in Three Virtual Investment Conferences in March
businesswire.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
prnewswire.com • -
Analyzing Teleflex (NYSE:TFX) & Viatar CTC Solutions (NYSE:VRTT)
thelincolnianonline.com •